98%
921
2 minutes
20
Recently, the International Conference on Harmonisation finalized an estimand framework for randomized trials that was adopted by regulatory bodies worldwide. The framework introduced five strategies for handling post-randomization events; namely the treatment policy, composite variable, while on treatment, hypothetical and principal stratum estimands. We describe an illustrative example to elucidate the difference between these five strategies for handling intercurrent events and provide an estimation technique for each. Specifically, we consider the intercurrent event of treatment discontinuation and introduce potential outcome notation to describe five estimands and corresponding estimators: 1) an intention-to-treat estimator of the total effect of a treatment policy; 2) an intention-to-treat estimator of a composite of the outcome and remaining on treatment; 3) a per-protocol estimator of the outcome in individuals observed to remain on treatment; 4) a g-computation estimator of a hypothetical scenario that all individuals remain on treatment; and 5) a principal stratum estimator of the treatment effect in individuals who would remain on treatment under the experimental condition. Additional insight is provided by defining situations where certain estimands are equal, and by studying the while on treatment strategy under repeated outcome measures. We highlight relevant causal inference literature to enable adoption in practice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338339 | PMC |
http://dx.doi.org/10.1080/00031305.2025.2468399 | DOI Listing |
Curr Med Res Opin
September 2025
Department of Internal Medicine, Taksim Training and Research Hospital, Istanbul, Turkey.
Introduction: Diabetes Mellitus is a chronic disease characterised by elevated plasma glucose (PG) levels. HbA1c has been widely utilized for diabetes diagnosis. However, certain conditions restrict its use.
View Article and Find Full Text PDFACS Sens
September 2025
METU MEMS Center, Ankara 06530, Türkiye.
Cardiovascular diseases (CVDs) remain a leading cause of death, particularly in developing countries, where their incidence continues to rise. Traditional CVD diagnostic methods are often time-consuming and inconvenient, necessitating more efficient alternatives. Rapid and accurate measurement of cardiac biomarkers released into body fluids is critical for early detection, timely intervention, and improved patient outcomes.
View Article and Find Full Text PDFJAMA Cardiol
September 2025
Department of Medicine, Cardiovascular Medicine, Stanford University, Stanford, California.
Importance: Consumer wearable technologies have wide applications, including some that have US Food and Drug Administration clearance for health-related notifications. While wearable technologies may have premarket testing, validation, and safety evaluation as part of a regulatory authorization process, information on their postmarket use remains limited. The Stanford Center for Digital Health organized 2 pan-stakeholder think tank meetings to develop an organizing concept for empirical research on the postmarket evaluation of consumer-facing wearables.
View Article and Find Full Text PDFClin Appl Thromb Hemost
September 2025
Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.
Hemophilia, an X-linked monogenic disorder, arises from mutations in the or genes, which encode clotting factor VIII (FVIII) or clotting factor IX (FIX), respectively. As a prominent hereditary coagulation disorder, hemophilia is clinically manifested by spontaneous hemorrhagic episodes. Severe cases may progress to complications such as stroke and arthropathy, significantly compromising patients' quality of life.
View Article and Find Full Text PDFJAMA Dermatol
September 2025
Department of Dermatology, University of Washington, Seattle.
Importance: Merkel cell carcinoma (MCC) is typically caused by the Merkel cell polyomavirus (MCPyV) and recurs in 40% of patients. Half of patients with MCC produce antibodies to MCPyV oncoproteins, the titers of which rise with disease recurrence and fall after successful treatment.
Objective: To assess the utility of MCPyV oncoprotein antibodies for early detection of first recurrence of MCC in a real-world clinical setting.